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Abstract
Activation of acid and neutral sphingomyelinases, and the
ensuing generation of ceramide, contributes to the biological
effects of tumour necrosis factor-a (TNF-a), one of which is
apoptosis. While the mechanisms of activation of sphingo-
myelinases by the cytokine are being unravelled, less is
known about regulation of their activity. Nitric oxide has
previously been shown to exert a cyclic GMP-dependent
inhibition of early apoptotic events triggered by TNF-a in the
U937 monocytic cell line. We therefore investigated whether
inhibition of sphingomyelinases by nitric oxide plays a role in
regulating such early events. We found that activation of both
acid and neutral sphingomyelinases, triggered in the first
minutes after U937 cell stimulation with TNF-a, is regulated in
an inhibitory fashion by nitric oxide, working through
generation of cyclic GMP and activation of protein kinase G.
Using a range of inhibitors selective for either sphingomye-
linase we found that the acid sphingomyelinase contributes to
activation of the initiator caspase-8 and early DNA fragmenta-
tion and that inhibition of the acid enzyme by nitric oxide
accounts for cyclic GMP-dependent early protection from
apoptosis. We also found that the protective effect by both
cGMP and acid sphingomyelinase inhibitors progressively
disappeared at laterstages of theapoptoticprocess. Inhibition
of sphingomyelinases represents a novel action of nitric
oxide, which might be of physiological relevance in regulating
initial phases of apoptosis as well as other biological actions
of ceramide.
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Introduction
Cell death via apoptosis is a biological process triggered by
several stimuli, among which are activation of death
receptors, e.g. CD95 and the p55 kDa receptor for tumour
necrosis factor-a (TNF-R1), nutrient deprivation, as well as
exposure to irradiation and chemotherapeutic agents.1
Intracellular pathways triggered by these stimuli include
activation of the caspase family of cysteine proteases and
mitochondria-associated processes that open the way to the
cascade of signalling events leading to cell death.1
Apoptosis plays a fundamental role in the development
of multicellular organisms and the maintenance of tissue
homeostasis. As a consequence of this, the signalling
pathways responsible for its initiation and progress are
tightly regulated at various levels by proteins and
messenger molecules.2 Among the latter, a relevant role
is played by nitric oxide (NO), which protects from
apoptosis induced by a variety of stimuli. Many of the
mechanisms through which NO inhibits apoptosis appear to
be independent of its ability to activate guanylate cyclase
and generate cyclic GMP (cGMP).3 Nevertheless, in some
cell systems the anti-apoptotic function of NO is mediated
by this cyclic nucleotide.3 There is some evidence to
suggest that cGMP acts by inhibiting downstream events,
namely cytochrome c release and opening of the
mitochondrial permeability transition pore,3,4 and/or over-
expression of Bax and of the Bcl-2 binding protein
BNIP3.3,5 In the case of apoptosis triggered by tumour
necrosis factor-a (TNF-a), however, cGMP-dependent
protection by NO appears also to involve inhibition of initial
events in the apoptotic cascade, i.e. recruitment to TNF-RI
of the DISC protein TRADD and ensuing activation of the
initiator caspase-8.6 This effect of NO/cGMP is due to
impairment of the TNF-a-triggered generation of the pro-
apoptotic lipid messenger ceramide and occurs in the first
minutes after cytokine addition to the cells.6 This observa-
tion implies that cGMP-dependent inhibition of ceramide
generation may function to inhibit apoptosis at its very
onset.
Ceramide contributes to apoptosis triggered not only by
TNF-a, but also by a variety of stimuli.7 – 9 For example,
inhibition of ceramide formation by NO/cGMP protects T
lymphocytes from apoptosis induced by CD95 and by
microbial antigens.10,11 Characterisation of the mechanisms
by which NO/cGMP inhibits the early wave of ceramide
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generation might, therefore, define the role of NO in
controlling the initiation of apoptosis by a variety of agents.
We have therefore investigated the mechanisms through
which NO inhibits early generation of ceramide triggered by
TNF-a. For this purpose we used the U937 pro-monocytic
cell line, which provides a model for TNF-a/ceramide
signalling in apoptosis devoid of any intrinsic NO synthase
activity.6,12 Among the various enzymes regulating the
cellular concentration of ceramide we have focused on acid
and neutral sphingomyelinases (A-SMase and N-SMase)
since they are activated by TNF-a early enough to account
for the initial wave of ceramide generation.7 – 9 Our results
show that exogenously administered NO, through genera-
tion of cGMP and activation of protein kinase G, inhibits
both enzymatic activities, and that inhibition of A-SMase
accounts for the early, cGMP-dependent protection from
TNF-a-induced apoptosis.
Results
To study the role of NO in regulating SMases, the kinetics of
activation by TNF-a of both A-SMase and N-SMase were
analyzed. U937 cells were treated with TNF-a (50 ng/ml) and
SMase activity measured in cell lysates at the optimum pH for
either enzyme (pH 5.5 and 7.4 for A-SMase and N-SMase,
respectively). As shown in Figure 1, activation by TNF-a of
both A-SMase and N-SMase was rapid in onset, as it was
clearly detected after 2 min of treatment with the cytokine,
peaked at 5 min and then diminished, returning to basal
values after 30 min. No further increase in A-SMase activity
was detected during the observation period (4 h). However,
there was a second prolonged phase of activation of N-
SMase, which commenced 90 min after TNF-a administration
and continued increasing for the rest of the observation period
(Figure 1B).
As we have shown previously in U937 cells, protection
by NO from TNF-a-induced apoptosis occurs in the first
minutes after cytokine administration.6 We therefore in-
vestigated the effects of NO on the first phase of A-SMase
and N-SMase activity, measured at their peak (5 min after
TNF-a). Results obtained are shown in Figure 2A.
Incubation of the cells with TNF-a in the presence of
increasing concentrations of the NO donor S-nitroso-
acetylpenicillamine (SNAP, 0 – 300 mM) resulted in inhibi-
tion of both SMase activities. This effect was dependent on
the concentration of SNAP, with apparent IC50s of
13.3+1.6 and 40+3.8 mM (n=6) for A-SMase and N-
SMase, respectively.
Figure 1 Kinetics of activation of A-SMase and N-SMase by TNF-a in U937
cells. Cells were treated with TNF-a (50 ng/ml) and samples collected at the
time points-indicated. A-SMase (A) and N-SMase (B) activities were
determined in cell lysates by measuring sphingomyelin hydrolysis to
phosphorylcholine at pH 5.5 (for A-SMase activity) and 7.4 (for N-SMase
activity). Values are expressed as %+S.E.M. over basal SMase activity
(1.28+0.6 and 0.52+0.3 nmol/mg h71 for A-SMase and N-SMase, respec-
tively) (n=5)
Figure 2 NO inhibits TNF-a-triggered A-SMase and N-SMase activities
through generation of cGMP and activation of protein kinase G. (A) U937 cells
were treated for 5 min with TNF-a (50 ng/ml) in the presence of increasing
concentrations of the NO donor SNAP. (B) Cells were treated for 5 min with
TNF-a with or without SNAP (300 mM), 8 Br-cGMP (1 mM), SNAP+ODQ (1 mM),
BAY 41-2272 (1 mM) and SNAP+KT5823 (1 mM). A-SMase and N-SMase
activities were measured in A and B as described in the legend to Figure 1 and
expressed as %+S.E.M. of those measured with TNF-a alone (100%).
Statistical values in the various samples are measured vs cells treated with
TNF-a alone (n=6)
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We then analyzed the dependence of the inhibitory
effect of NO on cGMP generation. To this end cells were
exposed to TNF-a in the presence of either the cell
membrane permeant cGMP analogue, 8 Br-cGMP
(1 mM), or BAY 41 2272 (1 mM), a compound that activates
guanylate cyclase through an NO-independent site.13
Under these conditions, activation of both A-SMase and
N-SMase by TNF-a was inhibited. Moreover, inhibition of
guanylate cyclase with the specific inhibitor H-[1,2,4]ox-
adiazolo[4,3-a]quinoxalin-1-one (ODQ) (1 mM),14 reversed
the inhibitory effect of SNAP (300 mM) on both A-SMase
and N-SMase activities (Figure 2B). The effect of SNAP
was likewise inhibited by its co-incubation with KT5823
(1 mM), an inhibitor of protein kinase G.15 Basal sphingo-
myelin hydrolysis was not modified when SNAP, ODQ,
BAY 41 2272,8 Br-cGMP or KT5823 were administered
without TNF-a (not shown). Taken together, these results
indicate that NO inhibits TNF-a-triggered A-SMase and N-
SMase activities via a mechanism involving activation of
guanylate cyclase, formation of cGMP and activation of
protein kinase G.
The contribution of A-SMase and N-SMase to apoptosis
stimulated by TNF-a has been widely studied and found to
vary depending on the cell system.8,9,12,16,17 To our
knowledge, however, there is no information on the specific
contribution of each enzyme to the early signalling events
leading to apoptosis. To elucidate this we used a range of
inhibitors, namely imipramine, tricyclodecan-9-yl xanthate
(D609) and monensin, which inhibit A-SMase activity,6,18,19
as well as scyphostatin and L-carnitine, which are inhibitors
of N-SMase activity.20,21 When administered alone no drug
had any effect on the basal level of sphingomyelin
hydrolysis (not shown). At the concentrations used,
however, imipramine (20 mM), monensin (1 mM) and D609
(25 mg/ml) were found to inhibit selectively TNF-a-triggered
A-SMase activity, while scyphostatin (1 mM) and L-carnitine
(10 mg/ml) appeared specific for the N-SMase activity
(Figure 3A,B).
We used these compounds to evaluate the relative
contribution of each SMase to the initial phases of
apoptosis triggered by administration of TNF-a in the
presence of the protein synthesis inhibitor cycloheximide
(CHX, 1 mg/ml).6 Under these conditions, the kinetics of A-
SMase and N-SMase activation were indistinguishable from
those observed with TNF-a alone (not shown). We
analyzed several hallmarks of apoptosis, i.e. activation of
the initiator caspase-8, measured 5 min after cytokine
addition, DNA fragmentation, measured from 1 to 3 h,
and exposure of phosphatidylserine on the outer leaflet of
the plasma membrane, measured at 3 h. Basal activity of
caspase-8, 10+0.9 picomol/min mg71 at time 0, was
increased by 71+4.5% after 5 min of treatment with TNF-
a/CHX (n=9). This increase was prevented by co-incubation
with imipramine, D609, or monensin (Figure 4A). Consis-
tently with this, A-SMase inhibitors prevented the reduction
in the amount of uncleaved, inactive procaspase-8 ob-
served after TNF-a/CHX treatment (Figure 4B). Similarly,
D609 and imipramine reduced TNF-a/CHX-induced DNA-
fragmentation and phosphatidylserine exposure (Figure
4C,D). By contrast, neither scyphostatin nor L-carnitine
had any appreciable effect on caspase-8 activation, DNA
fragmentation and phosphatidylserine exposure (Figure
4A – D). These results indicate that A-SMase contributes
to early apoptotic signalling triggered by TNF-a. In contrast,
N-SMase appears not to be involved at this stage of the
process.
We then investigated whether the cGMP-dependent
inhibition of A-SMase activity accounts for the NO/cGMP
protection from TNF-a-induced early apoptosis. To this end
we examined the effects of the cyclic nucleotide directly. As
shown in Figure 5, administration of 8 Br-cGMP inhibited
both TNF-a/CHX-triggered caspase-8 activation (at 5 min)
and DNA fragmentation (3 h time-point). When the cyclic
nucleotide was administered together with imipramine,
monensin or D609, neither caspase-8 activity nor DNA
fragmentation were inhibited further. Administration of the
long-chain natural ceramide analogue C16 ceramide
(30 mM) reversed the effects of 8 Br-cGMP and A-SMase
inhibitors on both TNF-a/CHX-triggered caspase-8 activa-
tion and DNA fragmentation. When administered alone,
C16 ceramide had no effects on caspase-8 activation and
DNA fragmentation in the period investigated (not shown,
n=5). These results strongly suggest that the cGMP-
dependent, early inhibitory effect of NO on TNF-a-induced
apoptosis was due to the ability of NO to inhibit A-SMase
activity and the ensuing generation of ceramide.
Finally, we investigated the role of this early mechanism
of protection in the progress of the apoptotic process. Table
1 shows the kinetics of DNA fragmentation measured 3, 4.5
and 6 h after administration of TNF-a/CHX. Protection by 8
Figure 3 Specificity of action of imipramine, monensin, D609, L-carnitine and
scyphostatin on TNF-a-triggered A-SMase and N-SMase activities. U937 cells
were treated for 5 min with TNF-a (50 ng/ml) with or without either imipramine
(imi, 20 mM), monensin (mon, 1 mM), D609 (25 mg/ml), L-carnitine (L-carn,
10 mg/ml) and scyphostatin (scypho, 1 mM). A-SMase (A) and N-SMase (B)
activities were measured as described in the legend to Figure 1 and expressed
as %+S.E.M. of those measured with TNF-a alone (100%). Statistical values
in the various samples are measured vs cells treated with TNF-a alone (n=5)
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Br-cGMP, D609 or imipramine was still significant at 4.5 h,
however, it was less than that measured at 3 h. At the 6 h
time-point, protection by these compounds was no longer
observed, indicating that cGMP-dependent inhibition of A-
SMase delays, rather than prevents, TNF-a/CHX-induced
apoptosis.
Discussion
The sphingolipid ceramide has recently been recognised as
an important intracellular second messenger, contributing to
regulation of various biological processes including inflamma-
tion, cell growth and differentiation. Often, however, the
outcome of ceramide signalling is induction of cell death via
apoptosis.7 Despite possible de novo formation of ceramide,
in the vast majority of cells sphingomyelin appears to be the
primary sphingolipid source for bioactive ceramide, thereby
emphasising the critical role for SMases in initiating ceramide-
activated apoptogenic signalling.
Two of these enzymes, A-SMase and N-SMase, have
been shown to contribute substantially to apoptosis
triggered by death receptors, although their contribution to
Figure 4 Involvement of A-SMase in caspase-8 activation, DNA fragmentation and phosphatidylserine exposure triggered by TNF-a/CHX. U937 cells were
treated with TNF-a (50 ng/ml)/CHX (1 mg/ml) with or without imipramine (imi, 20 mM), monensin (mon, 1 mM), D609 (25 mg/ml), L-carnitine (L-carn, 10 mg/ml) or
scyphostatin (scypho, 1 mM). Caspase-8 activity was measured after 5 min, as both cleavage of its specific substrate N-acetyl-IETD-7-amino-4-
trifluoromethylcoumarin (A), and proteolysis of the inactive zymogen, procaspase-8, detected by Western blotting (B). None of the treatment induced proteolysis
of procaspase-3, an effector caspase activated during late stages of apoptosis, which was used as an internal control. DNA fragmentation (C) and
phosphatidylserine exposure (D) were analyzed after 1 – 3 h, and after 3 h, respectively, of incubation with the cytokine, as detailed in the Materials and Methods
section. Values in A are expressed as %+S.E.M. of those measured with TNF-a/CHX alone (100%). Statistical values in the various samples are measured vs cells
treated with TNF-a/CHX (n=6)
Cell Death and Differentiation
Inhibition of sphingomyelinases by nitric oxide
R Barsacchi et al
1251
apoptosis appears to vary depending on the tissues and
cells investigated.8,9,16,17,22 The mechanisms of activation
of SMases have been extensively studied. The enzymes
are stimulated early after death receptor activation, down-
stream to recruitment to these receptors of proteins
involved in initiating their apoptotic signalling, i.e. FAN (for
N-SMase) and FADD (for A-SMase),17,23 with possible
involvement of other early signals.22,24,25 Expression of
dominant negative FAN and FADD gives rise to long-lasting
inhibition of apoptosis, restored only by exogenous
ceramide.16,17
Knowledge about the regulatory mechanisms for
SMases once they have been activated is still limited.
Regulation of these enzymes by intracellular messengers,
however, might be relevant to modulation of the whole
apoptotic process, as already shown with other early
apoptotic events.1,2 We now suggest that NO might be
one such regulatory messenger. In particular, NO was
found to inhibit in a concentration-dependent manner the
activation of both A-SMase and N-SMase triggered by TNF-
a in the first minutes after its administration to the cells.
This action by NO was found to be mediated through
stimulation of guanylate cyclase and to require activation of
protein kinase G. This latter may phosphorylate SMases
directly or through intermediate proteins, as proposed for
protein kinase C regulation of N-SMase.26 The observation
that NO regulates both SMases appears of particular
relevance for sphingolipid metabolism, since NO is
generated by a variety of stimuli in many physiological
and pathological conditions.14
To evaluate the biological relevance of this NO/cGMP
inhibition of SMases we investigated first the role of each
enzyme in the early phases of apoptosis induced by TNF-a/
CHX, by measuring activation of the initiator caspase-8 at
5 min and DNA fragmentation up to 3 h. Our results,
obtained using a range of structurally unrelated SMase
inhibitors, demonstrate an involvement of A-SMase in early
apoptosis triggered by TNF-a/CHX. This finding is in
agreement with a previous report in these cells.12 Since,
however, we found that TNF-a induced a second phase of
N-SMase (but not A-SMase) activation commencing about
90 min after cytokine administration, the later involvement
of this enzyme in apoptosis cannot be excluded.17
We then analyzed the importance of NO/cGMP inhibition
of A-SMase to the outcome of the apoptotic process.
Inhibition of TNF-a/CHX-triggered caspase-8 activity and
DNA fragmentation by the three A-SMase inhibitors used
was mimicked by 8 Br-cGMP, but was not enhanced by co-
administration of the cyclic nucleotide with the inhibitors.
These results indicate that inhibition of A-SMase by NO/
cGMP accounts for its protective effect. We found,
however, that such a mechanism of protection operates
only during early phases of apoptosis, since 8 Br-cGMP
and A-SMase inhibitors lost their protective function
progressively as apoptosis proceeded, becoming comple-
tely ineffective at later stages.
There are two implications of these observations. The
first is that the contribution of A-SMase to the apoptotic
process appears relevant only to its initial phases. Further
studies are needed in order to establish whether this occurs
Figure 5 Inhibition of A-SMase by 8 Br-cGMP accounts for its ability to
reduce TNF-a/CHX-triggered caspase-8 activation and DNA fragmentation. All
the groups shown in the figure were treated with TNF-a (50 ng/ml)/CHX (1 mg/
ml). 8 Br-cGMP (1 mM), imipramine (imi, 20 mM), monensin (mon, 1 mM), D609
(25 mg/ml), L-carnitine (L-carn, 10 mg/ml), scyphostatin (scypho, 1 mM) and C16
ceramide (cer, 30 mM) were added in various combinations as detailed on the y
axis. Caspase-8 activity (A) was measured after 5 min, DNA fragmentation (B)
after 3 h of incubation with the cytokine, as detailed in the Materials and
Methods section. Control in A and B represents caspase-8 activity and DNA
fragmentation, respectively, induced by TNF-a/CHX alone (n=5)
Table 1 Inhibition by cGMP and potentiation by A-SMase of TNF-a-induced
apoptosis are transient events
DNA fragmentation (%)
Time (h) 3 4.5 6
TNF-a 65.2+5.1 82.3+4.9 94.3+4.2
TNF-a+8 Br-cGMP 27.0+2.1*** 59.5+3.3** 88.1+4.8
TNF-a+imi 33.0+5.3*** 62.1+4.1** 95.6+6.1
TNF-a+D609 31.1+2.4*** 64.4+4.9* 93.2+5.2
U937 cells were treated with TNF-a (50 ng/ml)/CHX (1 mg/ml) with or without 8
Br-cGMP (1 mM), imipramine (imi, 20 mM) or D609 (25 mg/ml). DNA
fragmentation was measured after 3, 4.5 and 6 h of incubation with the
cytokine, as detailed in the Materials and Methods section. Values are expressed
as %+S.E.M. Statistical values in the various samples are measured vs cells
treated with TNF-a/CHX (n = 8)
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only in the cell system we investigated or if it is a more
general phenomenon. Such studies might also shed light
on the discrepancies in the literature about involvement of
A-SMase in apoptosis,8,9,16,17,22 which might be only
apparent, and ultimately depend on, the time-window at
which apoptosis is analyzed. The second implication is that
the protective action on NO exerted through cGMP delays,
rather then prevents apoptosis. This, together with the
observation that cGMP acts through A-SMase inhibition,
might be of importance in unravelling the overall mechan-
ism responsible for the early, cGMP-dependent regulation
of apoptosis. Location of A-SMase is still debated, despite
evidence indicating that the enzyme involved in apoptosis
is at the plasma membrane;12,27 – 29 consistent reports,
however, indicate mitochondria as a target for ceramide
apoptogenic signalling.29 – 31 Interestingly, the targets de-
scribed so far for the cGMP-dependent protective effect of
NO, namely the release of cytochrome c, the generation of
reactive oxygen species and the collapse of the mitochon-
drial membrane potential,3 – 5 have all been linked to
ceramide apoptogenic activity in mitochondria.29 – 31 An
intriguing hypothesis is, therefore, that inhibition of SMase
is the initial event in the cGMP-dependent protective action
of NO in apoptosis. Such an action might synergise with
another early protective action of NO, i.e. the cGMP-
independent, direct inhibition of cytochrome c oxidase in
the mitochondrial respiratory chain which contributes to the
maintenance of mitochondrial membrane potential during
apoptosis.32 In view of the fact that both guanylate cyclase
and cytochrome c oxidase are exquisitely sensitive to
nanomolar concentrations of NO14,33 it is conceivable that
NO is central to the fine-tuning of the mitochondria during
the apoptotic process.
Although all the results we have now described have
been obtained using exogenous NO, it is likely that
endogenously-generated NO will have the same effect.
Indeed, in cells endowed with an endothelial NO synthase,
TNF-a has been found to regulate its own apoptotic effect
through generation of NO.34 This generation of NO is
stimulated by the cytokine in a ceramide-dependent way.34
Interestingly, other agents such as high-density lipoprotein,
which do not induce apoptosis, have also been claimed to
release NO via a ceramide-dependent process.35 This
suggests that the reciprocal regulation between NO and
ceramide might be relevant not only for apoptosis but for
other, as yet not fully defined, biological endpoints.8
Materials and Methods
Materials
The following reagents were purchased as indicated: [N-methyl-14C]-
sphingomyelin, [14C]-thymidine and the Enhanced Chemilumines-
cence kit from Amersham Corporation (Little Chalfont, UK);
recombinant human TNF-a and ODQ from Alexis Italia (Florence,
Italy); N-acetyl-IETD-7-amino-4-trifluoromethylcoumarin from Eppen-
dorf (Hamburg, Germany); Bay 41-2272 from Bayer AG (Wuppertal,
Germany); D609 and SNAP from Calbiochem (Bad Soden, Germany);
antibodies against the aminoterminal portions of procaspase-8 and 3
from Santa Cruz Biotechnology (Santa Cruz, CA, USA); cell culture
media from GIBCO (Basel, Switzerland) except for foetal clone III
serum, obtained from Hyclone-Celbio, (Milan, Italy). Scyphostatin was
a kind gift by Dr. T Ogita (Sankyo Ltd., Tokyo, Japan). Monensin,
imipramine, C 16 ceramide and all the other chemicals were from
Sigma (St.Louis, MO, USA).
Cell culture and treatments
U937 cells were routinely grown at 378C, 5% CO2, in RPMI 1640
supplemented with 10 % heat-inactivated foetal clone III serum, 2 mM
glutamine, 100 U/ml streptomycin and 100 U/ml penicillin, and used
within the tenth week from thawing. All the experiments were carried
out in the above culture medium. Cell incubations with SNAP, ODQ, 8
Br-cGMP, D609, L-carnitine, monensin, scyphostatin, or CHX were for
10 min prior to TNF-a administration. Imipramine was added 1 h
before the experiments. SNAP was used at a concentration that does
not produce cytotoxic effects in U937 cells,6 and D609 under
conditions that do not stimulate ceramide generation.6
Measurement of SMase activities
Following pre-incubation with the various drug treatments, cell
samples (26106 cells) were treated with TNF-a (50 ng/ml at 378C)
or TNF-a (50 ng/ml) plus CHX (1 mg/ml), and treatment was stopped by
immersion of reaction tubes in a methanol/dry ice bath at the indicated
time-points. Cells were then centrifuged (1000 g for 2 min at 48C) and
the pellet washed once with ice-cold phosphate buffered saline. To
assay A-SMase activity cell pellets were resuspended in 0.2 ml of
0.1% Triton X-100 at 48C for 15 min and subsequently homogenised
by repeated squeezing through an 18-gauge needle. Homogenates
were then centrifuged (1000 g for 5 min at 48C) in order to remove
nuclei and cellular debris and the supernatant was incubated for 2 h at
378C in a buffer containing: 250 mM Na acetate, 1 mM EDTA, [N-
methyl-14C]-sphingomyelin (55 mCi/mmol; 50 000 d.p.m./assay), pH
5.5. To assay N-SMase activity, cell pellets were resuspended in
0.2 ml of a buffer consisting of: 0.2 % Triton X-100, 20 mM HEPES,
1 mM MgCl2, 2 mM EDTA, 5 mM dithiothreitol, 0,1 mM Na3VO4,
30 mM p-nitrophenylphosphate, 10 mM b-glycerophosphate, 750 mM
ATP, 1 mM phenylmethylsulfonyl fluoride, 10 mM leupeptin, 10 mM
pepstatin, 5 mg/ml soybean trypsin inhibitor and 2 mg/ml aprotinin, pH
7.4. After 5 min incubation on ice, cells were homogenised as above.
Cell lysates were then incubated for 2 h at 376C in a buffer containing
20 mM HEPES, 1 mM MgCl2 and [N-methyl-
14C]-sphingomyelin
(55 mCi/mmol; 50 000 d.p.m./assay), pH 7.4. Reactions for both A-
SMase and N-SMase were stopped by addition of 250 ml of ice-cold
CHCl3 : MeOH (2 : 1, vol : vol) and 250 ml of ice-cold H2O. Phosphor-
ylcholine thus produced was separated from sphingomyelin by
sequential washing with 800 ml of ice-cold CHCl3 : MeOH (2 : 1,
vol : vol), 500 ml of CHCl3 and 750 ml of CHCl3 : MeOH : H2O
(2 : 47 : 48, vol : vol : vol). Aqueous and organic phases were then
collected separately and radioactive phosphorylcholine in the aqueous
phase counted by liquid scintillation in a Beckman b-counter. Non-
hydrolysed, radioactive sphingomyelin in the organic phase was
routinely measured as an internal control. Samples containing either
purified A-SMase or N-SMase (Sigma) were assayed in parallel as
positive controls. Results were normalised to the protein content
evaluated by the bicinchoninic acid procedure (BCA; Pierce, IL, USA).
Measurement of caspase-8 activation
Aliquots of 26106 cells, pre-incubated with the various drug
treatments described above, were treated for 5 min with TNF-a
(50 ng/ml) in the presence of CHX (1 mg/ml), washed in 150 mM NaCl,
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1 mM EDTA, 2 mM Na2P2O6, 30 mM NaF, 20 mM HEPES, pH 7.5 and
lysed at the indicated time-points in the same buffer containing 1%
Triton X-100, 0.1 mM phenylmethylsulphonylfluoride, 10 mg/ml leu-
peptin and 10 mg/ml aprotinin. Soluble proteins (100 mg) were diluted
in a reaction buffer containing a final concentration of 25 mM HEPES,
100 mM NaCl, 5 mM dithiothreitol, 1 mM EDTA, 0.1% CHAPS and
10% sucrose. Caspase-8 activity was assayed in a Perkin-Elmer LS50
fluorometer, equipped with 400 nm excitation and 505 nm emission
filters, by measuring for 1 h at 378C the fluorescence emitted by the
cleaved caspase-8 substrate, N-acetyl-IETD-7-amino-4-trifluoro-
methylcoumarin (25 mM), calibrated with respect to a 7-amino-4-
trifluoromethylcoumarin concentration curve. Western blot analyses of
procaspase-8 were carried out with 30 mg of soluble proteins,
separated on 12% SDS – PAGE and transferred onto nitro-cellulose
membranes. Non-specific sites were blocked before immunolabelling
by incubation for 1 h at room temperature with blotting buffer (PBS
containing 0.1% Tween and 5% non-fat milk). The membranes were
incubated overnight in blotting buffer with the anti-procaspase-8
antibody and washed five times for 1 h with blotting buffer. The
secondary anti-mouse antibody was then added for 30 min. After
several washes of the membranes in blotting buffer, the antigens were
revealed by Enhanced Chemiluminescence according to the manufac-
turer’s instructions. As an internal control, all Western blots were
subsequently stripped of the first antibody and reprobed with the
antibody recognising procaspase-3. Stripping of the first antibody was
carried out by incubating nitrocellulose filters for 30 min at 528C with a
buffer consisting of: 62.5 mM Tris-HCl, 2 % SDS, 1% b-mercaptoetha-
nol, pH 6.7. Filters were then washed twice for 10 min with 100 mM
Tris-HCl, 0.1% Tween 20, pH 7.4, before equilibration for 1 h in
blotting buffer.
Apoptosis detection
Secondary DNA fragmentation was quantified using the filter binding
assay as described.6 Briefly, the cells were labelled overnight with
[14C]-thymidine (0.05 mCi/ml) and incubated for a further 6 h in a
medium containing unlabelled thymidine (1 mg/ml) before incubation
with or without the various compounds and treatment with TNF-a
(50 ng/ml) plus CHX (1 mg/ml). At the indicated time-points the cells
were sedimented (1000 r.p.m., 5 min at 48C) and the pellet was
resuspended in saline containing: 140 mM NaCl, 5 mM KCl, 5 mM
glucose, 5 mM EDTA, 4 mM Na HCO3, pH 8.3. Aliquots of 0.5610
6
cells were then loaded onto protein adsorbing (polyvinylchloride) filters
(25 mm, 2 mm pore; Nuclepore, Pleasanton, CA, USA), washed with
the same buffer and lysed with a solution containing 0.2% sarkosyl,
2 M NaCl and 40 mM EDTA, pH 10.1. Filters were rinsed with EDTA
(20 mM, pH 10.1) and then removed from the filter holders which were
washed twice with 0.4 N NaOH. Radioactivity was counted in the
lysates, EDTA washes, filters and filter holder washes.
Phosphatidylserine exposure at the external surface of the plasma
membrane was detected by analysis of aliquots of 66104 cells,
stained for 15 min with FITC-labelled annexin V (1 mg/ml), using a
Fluorescence-Activated Cell Sorter (FACStar Plus, Becton Dickinson,
Sunnyvale, CA, USA) as described previously.10
Statistical analysis
The results are expressed as means+standard error of the mean
(S.E.M.); n represents the number of individual experiments. Statistical
analysis was carried out using the Student’s t-test for unpaired
variables (two-tailed). The asterisks *, ** and *** in the figure panels
and in Table 1 refer to statistical probabilities (P) of 50.5, 50.01 and
50.001, respectively, measured for the cells treated in the various
experimental conditions vs the cells treated with TNF-a alone (Figures
1 – 3) or TNF-a and CHX (Figure 4 and Table 1).
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